

RECEIVED
CENTRAL FAX CENTER
JAN 15 2010

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S) : Bowen, et al.
SERIAL NO. : 10/502,080
FILED : 10/8/2004
FOR : Solenopsin A, B and Analogs as Novel Angiogenesis Inhibitors
GROUP ART UNIT : 4161
Examiner : Brian M. Gullledge

Mail Stop After Final
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Amendment/Response in Application

SIR:

In the above-referenced patent application, in response to the office action of June 11, 2009 and the office action of January 13, 2010, please amend the claims as is provided hereinbelow. Note that originally filed claims 3-4, 6, 9-14 and 16-37 were cancelled *without prejudice* pursuant the Examiner's restriction requirement and Applicant's election of invention. The claims cancelled in the previous office action were also canceled without prejudice in order to advance prosecution of the present application, as is the subject matter which is deleted from the previously pending claims and presented herein.

S.N. 10/502,080
B40-002.Amendment Response 1-10

1